Original Research Article
Year: 2020 | Month: April-June | Volume: 5 | Issue: 2 | Pages: 53-55
Hematological and Molecular Response Assessment of CP-CML Patients Treated With Imatinib: An Experience from a Tertiary Care Hospital in India
Namrata Bhutani1, Deepika Arora2, Neha Bhutani3
1Department of Biochemistry, Vardhaman Mahavir Medical College & Safdarjung Hospital, New Delhi, India
2Department of Anaesthesia, Royal London Hospital, NHS Barts Health, London, United Kingdom
3ESIC Dental College, Rohini, New Delhi, India.
Corresponding Author: Neha Bhutani
ABSTRACT
Background: Imatinib is a common drug for the treatment of CML. This study describes our experience with response to imatinib in patients of CML in a tertiary care hospital in India.
Materials and methods: After initiation of imatinib therapy, hematological response was monitored at regular intervals & molecular response assessed, in 30 newly diagnosed CML patients.
Results: Time to achieve CHR(THR) ranged from 1- 4.5 months. 26(86.66%) patients achieved CHR by the end of 3 months(n=17) had Optimal response (table 4),23.33% (n=7) warning and 20% (n=6) had failure to therapy. 2 patients were lost to follow-up and therefore excluded from the analysis, 1 patient had progression to BC and death, 1 patient had loss of CHR and 1 had progression to BC & death.
Conclusion: Imatinib mesylate is highly effective in the treatment of chronic phase CML and should be considered as the drug of first choice in CML. Molecular response evaluation after six months can predict the subsequent molecular response and can also be used as a surrogate monitor of marrow cytogenetic response.
Keywords: chronic myeloid leukemia, imatinib, drug resistance.